Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC 45 Cash-to-Debt is 0.47 as of Jun. 2026, which is 31% above its 10-year median of 0.36. GuruFocus rates LSE:SPEC with a GF Score™ of 45/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Inspecs Group ranks worse than 72.92% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Inspecs Group's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.47.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Inspecs Groupcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Inspecs Group's Cash-to-Debt or its related term are showing as below:
LSE:SPEC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.36 Max: 1.59
Current: 0.47
During the past 8 years, Inspecs Group's highest Cash to Debt Ratio was 1.59. The lowest was 0.08. And the median was 0.36.
LSE:SPEC's Cash-to-Debt is ranked worse than 72.92% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs LSE:SPEC: 0.47
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Inspecs Group Cash-to-Debt Related Terms
Inspecs Group Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LSE:SPEC vs ISRG, BDX, RMD: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (LSE:SPEC) has a Cash-to-Debt of 0.47 as of Jun. 2026. This is 31% above median its historical median of 0.36. Over the past decade, Inspecs Group's Cash-to-Debt has ranged from 0.08 to 1.59. According to the industry distribution chart, Inspecs Group ranks #614 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 72.9%.
Is Inspecs Group's Cash-to-Debt too high?
Inspecs Group's current Cash-to-Debt of 0.47 is 31% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.59. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Inspecs Group's value of 0.47 is 71.3% below this industry median. Based on the distribution chart, Inspecs Group ranks #614 out of 842 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Inspecs Group has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #614 out of 842 companies for Cash-to-Debt. This places Inspecs Group in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Inspecs Group's value of 0.47 is 71.3% below this benchmark. Historically, Inspecs Group's own Cash-to-Debt has ranged from 0.08 to 1.59 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 1.64, Inspecs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current Cash-to-Debt of 0.47 is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Cash-to-Debt is 0.47, which is 31% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.94 — trading 61.2% above its estimated fair value. The current Cash-to-Debt is 0.47, which is 31% above median its 10-year median of 0.36 and 71.3% below the Medical Devices & Instruments industry median of 1.64. Inspecs Group's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current Cash-to-Debt is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.94 is trading 61.2% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
Cash-to-Debt: 0.47 (31% above median its 10-year median of 0.36)
GF Value™: £0.58 vs. price of £0.94 (61.2% above fair value)
Industry Position: 71.3% below the Medical Devices & Instruments median (#614 of 842)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
45GF Score
Get the complete analysis for LSE:SPEC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
